Fluorescent phospholipid ether compounds, compositions, and methods of use
The invention generally relates to novel fluorescent phospholipid compounds, compositions comprising these compounds, and diagnostic methods utilizing these compounds. A preferred compound of the present invention has the following structural formula:
1. A method of determining cancer in a subject, comprising:
administering to a subject a composition comprising a phospholipid ether compound selected from the group consisting of:
and
determining cancer in the subject by detecting the phospholipid ether compound in the subject.
2. The method of claim 1 , wherein the phospholipid ether compound has a structure:
3. The method of claim 1 , wherein the phospholipid ether compound has a structure:
4. The method of claim 1 , wherein the phospholipid ether compound has a structure:
5. The method of claim 1 , wherein the composition comprises a pharmaceutically acceptable carrier.
6. The method of claim 1 , wherein the subject is human.
7. The method of claim 1 , wherein the cancer is selected from the group consisting of melanoma, colorectal adenocarcinoma, uterine carcinoma, pancreatic carcinoma, ovarian adenocarcinoma, glioblastoma, clear cell carcinoma, and prostate adenocarcinoma.
8. The method of claim 1 , wherein the phospholipid ether compound is detected using fluorescence.
9. A method of detection of a phospholipid ether compound within a subject, comprising:
administering to a subject a composition comprising a phospholipid ether compound selected from the group consisting of:
and
detecting retention of the phospholipid ether compound within an organ within the subject.
10. The method of claim 9 , wherein the phospholipid ether compound has a structure
11. The method of claim 9 , wherein the phospholipid ether compound has a structure:
12. The method of claim 9 , wherein the phospholipid ether compound has a structure:
13. The method of claim 9 , wherein the composition comprises a pharmaceutically acceptable carrier.
14. The method of claim 9 , wherein the subject is human.
15. The method of claim 9 , wherein retention of the phospholipid ether compound is detected using fluorescence.
16. The method of claim 9 , wherein the organ is selected from the group consisting of colon, rectum, small bowel, esophagus, stomach, duodenum, uterus, pancreas and common bile duct, bronchi, sinus, lung, bladder, kidney, abdominal cavity, and thoracic cavity.